Polygenic risk separates two very different skin cancer trajectories in autoimmune hypothyroidism
Autoimmune hypothyroidism does not appear to carry a uniform skin cancer risk. In a large genetic analysis spanning more than 650,000 people in All of Us and FinnGen, the excess risk tied to hypothyroidism depended heavily on inherited background, with a hypothyroidism polygenic risk score, or H-PRS, flipping the expected pattern in a clinically meaningful way.
Among FinnGen participants, autoimmune hypothyroidism tracked with a higher hazard of skin cancer, while higher H-PRS tracked with lower risk. Those opposing signals are not a statistical curiosity; they suggest that the endocrine diagnosis may be acting as a marker for more than one biological pathway. In one group, autoimmune thyroid disease may coexist with the immune and inflammatory milieu that accompanies elevated cancer susceptibility. In another, the underlying genetic architecture linked to hypothyroidism may represent a distinct phenotype with lower skin cancer liability.
A single diagnosis can hide multiple risk states. This dataset makes that plain.
Divergent signals from autoimmune hypothyroidism and H-PRS
FinnGen provided the clearest estimate of the association. Autoimmune hypothyroidism was associated with increased skin cancer hazard, with a hazard ratio of 1.10 and a 95% confidence interval of 1.06 to 1.15. By contrast, H-PRS moved in the opposite direction: each 1-SD increase was associated with a lower skin cancer hazard, with a hazard ratio of 0.97 and a 95% confidence interval of 0.95 to 0.98.
The interaction term sharpened the interpretation. The hypothyroidism×H-PRS interaction was negative, with a hazard ratio of 0.94 and a 95% confidence interval of 0.91 to 0.98, meaning the hypothyroidism-associated excess risk was concentrated among people with lower hypothyroidism genetic liability. In practical terms, the same clinical label did not mean the same risk profile across patients.
Replication mattered here. The hypothyroidism and H-PRS associations held in All of Us, and the same H-PRS risk gradients appeared for melanoma, basal cell carcinoma, and squamous cell carcinoma in both cohorts. Those parallel findings make the pattern harder to dismiss as a one-off cohort artifact or a signal confined to a single tumor type.
Skin cancer risk rises when H-PRS and SC-PRS point in opposite directions
The study did not stop at hypothyroidism genetics. Investigators also layered in a skin cancer polygenic risk score, or SC-PRS, to see whether joint modeling could identify patients at especially high risk.
It could. Among patients with hypothyroidism, predicted 10-year skin cancer risk rose as SC-PRS increased and H-PRS decreased. Combined clinical-genetic profiles yielded hazard ratios ranging from 2.32 at the 20th H-PRS and 80th SC-PRS percentiles to 3.37 at the 5th and 95th percentiles. Those estimates exceeded published point estimates for established dermatologic risk factors cited in the work, which makes the interaction more than an academic observation. It suggests that inherited liability can amplify, or dampen, the usual clinical signal in ways that matter for surveillance.
For women aged 55, a group near the median age of diagnosis and representing the more commonly affected sex, the contrast was striking. Ten-year skin cancer risk reached 14.9% in the highest-SC-PRS and lowest-H-PRS quartiles, with a 95% confidence interval of 8.4% to 20.9%, versus 2.8% in the opposite quartiles, with a 95% confidence interval of 1.0% to 4.7%.
Why thyroid autoimmunity may intersect with cutaneous malignancy risk
The biology is plausible, even if it remains incomplete. Autoimmune hypothyroidism reflects immune dysregulation, and chronic immune activation can alter tumor surveillance, inflammatory signaling, and the tissue environment in which malignant clones emerge. Skin cancer is especially sensitive to these forces because ultraviolet injury, local immune escape, and host repair capacity all shape whether damaged keratinocytes or melanocytes progress toward clinically apparent disease.
Genetics may be separating at least two mechanisms. One pathway may capture immune-mediated hypothyroidism linked to cancer-prone biology, while another may reflect inherited liability to hypothyroidism that does not carry the same oncologic burden. The inverse association between H-PRS and skin cancer supports that interpretation. Rather than reading hypothyroidism as a single exposure, the data argue for a stratified view in which genetic architecture helps identify who among these patients is most likely to benefit from earlier dermatologic attention.
What a risk-stratified clinic could look like
If these findings hold in further validation, the clinical consequence is straightforward: not every patient with autoimmune hypothyroidism would require the same skin cancer surveillance intensity. A patient with high SC-PRS and low H-PRS could plausibly sit in a substantially different risk tier than a patient with the reverse profile, even when both carry the same endocrine diagnosis.
That would matter most for prevention. Earlier skin examinations, tighter counseling about self-surveillance, and a lower threshold for dermatology referral could be directed toward patients whose combined score profile places them at the top of the risk distribution. The data also raise the possibility that genetic information could refine preventive counseling beyond what clinicians infer from thyroid disease alone.
The preprint format still leaves important limits. These findings have not undergone peer review, and the study itself cannot establish causality. The reported associations are strong enough to support risk stratification hypotheses, but not yet enough to justify changes in routine practice. The next step is external validation in additional populations, followed by testing whether PRS-guided surveillance actually improves earlier detection or changes outcomes in skin cancer prevention.